The company received US FDA approval for the Prospera SCS System in March of this year. Credit: BIOTRONIK Neuro.

Biotronik Neuro has announced that data from the BENEFIT-02 trial demonstrated the effectiveness of the RESONANCE multiphase stimulation paradigm.

The stimulation is utilised in the company’s Prospera spinal cord stimulation (SCS) system for the treatment of chronic pain in patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Using less power and an advanced integrated circuit design, RESONANCE offers a continuous, spatially and temporally distributed therapeutic pulse pattern across the spinal cord.

The randomised, single-blind, multicentre prospective feasibility study evaluated the effectiveness and safety of the new charge-distributed multiphase stimulation paradigm during an extended SCS study.

It involved participants with chronic low back and leg pain. They have been randomised to multiphase SCS therapy after a successful commercial SCS trial.

Therapy was delivered through an investigational external pulse generator and existing leads during the testing period of 11–12 days after washout.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study demonstrated no statistically significant difference in mean NRS reduction or per cent pain relief between multiphase therapies A and B among the 65 patients who completed the trial.

Furthermore, 63.9% of participants reported greater pain relief with multiphase compared with commercial SCS therapy in the at-home setting.

Biotronik Neuro president Todd Langevin said: “We developed Prospera to offer patients sustainable pain relief and we believe its proactive care model will have a clinically meaningful impact on lowering long-term failure rates and reducing the service burden of SCS.”

In March of this year, the company received approval from the US Food and Drug Administration (FDA) for the Prospera SCS System.

This system includes a patient-centric care model, Embrace One, which facilitates proactive care through automatic, objective, daily remote monitoring.